Silo Pharma (SILO) risk factors

64 risks, 17 new, 2 dropped, 4 reworded since the prior year. Silo Pharma added numerous risks regarding a new cryptocurrency treasury strategy, including regulatory classification, staking, and custody. Share counts and warrant overhang shifted significantly, with warrant counts rising from 2.2 million to 10.2 million.

49 risks. Silo Pharma relies entirely on raising external capital to fund development of early-stage central nervous system therapeutics and psychedelics. Operations depend heavily on licenses from institutions like Columbia University and the University of Maryland, Baltimore. Regulatory hurdles surrounding controlled substances such as psilocybin and psilocin pose major threats to commercialization.